DYAINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
DYADIC INTERNATIONAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.38−0.03 (-7.35%)
Close on Oct 19, 2026
- Market cap
- $13.88M
- P/E (TTM)
- –
- Dividend yield
- –
DYADIC INTERNATIONAL INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Grant [Member] | $1.86M | – | – | – | – | 60.1% | – |
| Research And Development [Member] | $967.31K | $1.61M | $2.55M | $2.68M | $2.40M | 31.3% | -39.7% |
| License [Member] | $265.00K | $890.17K | $352.94K | $247.06K | $0 | 8.6% | -70.2% |
By region
From the segment and revenue-disaggregation notes of Dyadic International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.